Centessa Pharmaceuticals PLC ADR

NASDAQ CNTA

Data sourced from

and

Daily

Download Data

Centessa Pharmaceuticals PLC ADR Price to Book Ratio (P/B) on June 03, 2024: 3.97

Centessa Pharmaceuticals PLC ADR Price to Book Ratio (P/B) is 3.97 on June 03, 2024, a 174.93% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Centessa Pharmaceuticals PLC ADR 52-week high Price to Book Ratio (P/B) is 4.97 on March 22, 2024, which is 25.28% above the current Price to Book Ratio (P/B).
Centessa Pharmaceuticals PLC ADR 52-week low Price to Book Ratio (P/B) is 1.44 on June 05, 2023, which is -63.63% below the current Price to Book Ratio (P/B).
Centessa Pharmaceuticals PLC ADR average Price to Book Ratio (P/B) for the last 52 weeks is 2.97.

NASDAQ: CNTA

Centessa Pharmaceuticals PLC ADR

CEO	Dr. Saurabh Saha M.D., Ph.D.
IPO Date	May 28, 2021
Location	United Kingdom
Headquarters	1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Employees	77
Sector	Healthcare
Industry	Biotechnology

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key trends